Astellas Pharma's Total Assets for the quarter that ended in Dec. 2024 was $22,440 Mil.
Warning Sign:
If a company builds assets at 11% a year, faster than its revenue growth rate of 5.8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Astellas Pharma's average Total Assets Growth Rate was 5.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 18.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 11.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 7.90% per year.
During the past 13 years, Astellas Pharma's highest 3-Year average Total Assets Growth Rate was 23.40%. The lowest was -4.10%. And the median was 7.00%.
The historical data trend for Astellas Pharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Astellas Pharma's Total Assets for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (OTCPK:ALPMY) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Astellas Pharma's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Astellas Pharma Total Assets Related Terms
Thank you for viewing the detailed overview of Astellas Pharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALPMY has been successfully added to your 